Drug · Small Molecule

Vinorelbine

CI-DRUG-00000639Explore in graph →NCIt C1275 CHEMBL553025 CIViC Approved

Regulatory

Approvals (10)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	Lung Non-Small Cell Carcinoma	Vinorelbine injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC Vinorelbine injection is a vinca alkaloid indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) ( 1 ) As a single agent for first-line treatment of patients with metastatic NSCLC ( 1 )	approved	Jul 22, 2009	openfda

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 16 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	47	25	89	311	10	CA, US	May 9, 2007	1995-02
Malignant Lung Neoplasm	Approved	Phase 4	9	5	32	92	1	US	Jul 22, 2009	1995-02
Malignant Breast Neoplasm	Phase3	Phase 3	16	9	34	110	0	—	—	1998-10
Hodgkin Lymphoma	Phase3	Phase 3	3	3	3	12	0	—

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RRM1 Underexpression1
Gemcitabine + Paclitaxel

Clinical trials

Trials with this intervention (319)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 319 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03442673	Chemotherapy and G-CSF for Mobilization(MOCCCA)	completed	Phase 2	137	Insel Gruppe AG, University Hospital BernOTHER	1	Mar 28, 2025	clinicaltrials
NCT02489903	RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Molecule

Record

Kind: Small Molecule
Mechanism: Tubulin inhibitor
Targets: 15 genes
UNII: 253GQW851Q
Aliases: 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine, 5'-Nor-Anhydrovinblastine, AJ-VINORELBINE, Dihydroxydeoxynorvinkaleukoblastine, Navelbin, NAVELBINE, Nor-5'-Anhydrovinblastine, NSC-760087, Vinorelbina, Vinorelbine, Vinorelbine base, Vinorelbine Tartrate, VINORELBINE TARTRATE

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (19)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01CA04	VINORELBINE
DIN (Health Canada)	02091283	NAVELBINE
DIN (Health Canada)